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Abstract
Background: Homozygous Familial Hypercholesterolemia (HoFH) is an inherited 
recessive condition associated with extremely high levels of low‐density lipoprotein 
(LDL) cholesterol in affected individuals. It is usually caused by homozygous or 
compound heterozygous functional mutations in the LDL receptor (LDLR). A num-
ber of mutations causing FH have been reported in literature and such genetic hetero-
geneity presents great challenges for disease diagnosis.
Objective: We aim to determine the likely genetic defects responsible for three cases 
of pediatric HoFH in two kindreds.
Methods: We applied whole exome sequencing (WES) on the two probands to 
determine the likely functional variants among candidate FH genes. We addi-
tionally applied 10x Genomics (10xG) Linked‐Reads whole genome sequencing 
(WGS) on one of the kindreds to identify potentially deleterious structural vari-
ants (SVs) underlying HoFH. A PCR‐based screening assay was also established 
to detect the LDLR structural variant in a cohort of 641 patients with elevated 
LDL.
Results: In the Caucasian kindred, the FH homozygosity can be attributed to two 
compound heterozygous  LDLR damaging variants, an exon 12 p.G592E missense 
mutation and a novel 3kb exon 1 deletion. By analyzing the 10xG phased data, we 
ascertained that this deletion allele was most likely to have originated from a Russian 
ancestor. In the Mexican kindred, the strikingly elevated LDL cholesterol level can 
be attributed to a homozygous frameshift LDLR variant p.E113fs.
Conclusions: While the application of WES can provide a cost‐effective way of iden-
tifying the genetic causes of FH, it often lacks sensitivity for detecting structural 
variants. Our finding of the LDLR exon 1 deletion highlights the broader utility of 
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1 |  INTRODUCTION
Mutations in the low‐density lipoprotein (LDL) receptor 
(LDLR; OMIM accession: 606945) underlie most cases of 
familial hypercholesterolemia (FH). This monogenic dis-
order represents approximately 4% of patients with plasma 
levels of LDL cholesterol (LDL‐C) above the 95th percen-
tile and normal levels of other lipoproteins. The prevalence 
of heterozygous FH (HeFH) within the general population 
has been traditionally estimated to be in the range of 1 in 
400 to 500 (Goldstein, Hobbs, & Brown, 2007), but more 
contemporary studies suggested that the frequency can be as 
high as 1 in 200 in the European general population (Benn, 
Watts, Tybjaerg‐Hansen, & Nordestgaard, 2012, 2016; 
Nordestgaard et al., 2013). It is typically associated with 
premature coronary artery disease (CAD) and peripheral 
vascular disease. Other clinical findings include tendon xan-
thomas, xanthelasma, and arcus corneae. However, the phe-
notype of FH can manifest in a much more severe way when 
individuals harbor homozygous or compound HeFH variants. 
Individuals with HeFH have a mean LDL‐C plasma level of 
298 mg/dl whereas those with HoFH have a mean of 625 mg/
dl (Goldstein et al., 2007). Among 65 HeFH patients seen at 
the UCSF Lipid Clinic with known deleterious LDLR muta-
tions, the mean LDL‐C was 288 mg/dl (unpublished observa-
tions: CRP, JPK, MJM). Although deleterious mutations in 
the LDLR are the most common causes of severely elevated 
LDL‐C, mutations in other genes account for a few cases. 
Among these genes are APOB (apolipoprotein B; OMIM ac-
cession: 107730), coding for a ligand for the LDLR; PCSK9 
(proprotein convertase subtilisin/kexin type 9; OMIM acces-
sion: 607786); LDLRAP1 (low‐density lipoprotein receptor 
adaptor protein 1; OMIM accession: 605747), STAP1 (sig-
nal transducing adaptor family member 1; OMIM accession: 
604298), and CYP7A1 (cholesterol 7α‐hydroxylase; OMIM 
accession: 118455) (Hegele et al., 2015; Pullinger, Kane, & 
Malloy, 2003), LIPA (lysosomal acid lipase; OMIM acces-
sion: 613497) (Pullinger et al., 2015), ABCG5 (ATP binding 
cassette subfamily G member 5; OMIM accession: 605459) 
and ABCG8 (ATP binding cassette subfamily G member 8; 
OMIM accession: 605460) (Pullinger et al., 2003).
Establishing a definitive genetic etiology of FH is import-
ant because it is useful in guiding physicians in determining 
the most effective management on the basis of a specific mu-
tation. For example, if a patient is homozygous, or compound 
heterozygous, for damaging or null LDLR variants, statins 
alone will have limited effect because these drugs work by 
increasing the LDL receptor expression on the cell surface 
thereby removing circulating LDL and remnant lipoproteins 
from the blood. In the case of defects in ABCG5 and ABCG8 
transporters the dyslipidemia of FH is compounded by hyper-
absorption of sterols. Agents with mechanisms of action not 
dependent on the presence of competent LDL receptors (such 
as ezetimibe, niacin, bile acid ion‐exchange resins, and lom-
itapide) are useful. In patients with LIPA deficiency statins 
are likely to exacerbate the disease by increasing endocytosis 
of cholesteryl esters.
Here we report two families with three patients with rare 
HoFH. In the first kindred, one homozygous and seven het-
erozygous patients were identified. The other kindred in-
cluded two homozygous and three heterozygous patients.
2 |  METHODS
2.1 | Study patients
Two probands with HoFH were referred to the UCSF 
Pediatric Lipid Clinic. The first was a 5‐year old Caucasian 
girl who presented with a severely elevated level of LDL 
and tuberous and tendinous xanthomas. The second was a 
21‐month old girl of Hispanic ancestry who, when first seen, 
also had a severely elevated level of LDL‐C. She had some 
cutaneous xanthomas at birth. For each kindred, blood sam-
ples were also obtained from available family members; 11 
relatives for the first kindred and four for the second. All 
study participants gave written informed consent prior to 
their enrollment in the study, which adhered to the World 
Medical Association Declaration of Helsinki and were ap-
proved by the University of California San Francisco (UCSF) 
Committee on Human Research Institutional Review Board 
as part of the UCSF Human Research Protection Program. 
Children were included with parental consent.
Funding information
This work was supported by the Joseph 
Drown Foundation, the Campini 
Foundation, and by gifts from Peter Read, 
Harold Dittmer, Susan Boeing and Donald 
Yellon. K.H.Y.W was supported by the 
National Institutes of Health (NIH) under 
award R01 HG005946 to P.‐Y.K. The 
content is solely the responsibility of the 
authors and does not necessarily represent 
the official views of the NIH.
Linked‐Read WGS in detecting SVs in the clinical setting, especially when HoFH 
patients remain undiagnosed after WES.
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2.2 | DNA preparation and 
biochemical analyses
Blood was collected from the two probands and their par-
ticipating family members, after overnight fasting, in tubes 
containing 0.1% ethylenediaminetetraacetic acid. When these 
samples were collected, none of the participants were taking 
lipid medications. Blood was centrifuged at 3,000  rpm for 
20 min at 4°C and plasma separated. An automated chemical 
analyzer (COBAS Chemistry analyzer) was used to measure 
levels of total cholesterol (TC), HDL cholesterol (HDL‐C), 
and triglyceride (TG) in plasma as described previously 
(Pullinger et al., 2008, 1995). The Friedewald method was 
used to calculate LDL‐C (Friedewald, Levy, & Fredrickson, 
1972). Genomic DNA was extracted using the Wizard puri-
fication kit (Qiagen). The Genbank reference sequences used 
for sanger validations were: LDLR NG_009060.1; APOB 
NG_011793.1; MYL5 NM_002477.1; MSR1 NG_012102.1; 
ABCA1 NG_007981.1; SPTY2D1 NM_194285.3; LCAT 
NG_009778.1; PCTP NM_021213.4; LPIN1 NG_012843.2; 
STAB1 NM_015136.3; ABCC2 NG_011798.2; PGS1 
NM_024419.5; OSBPL1A NG_029432.1; MC4R 
NG_016441.1.
2.3 | Whole exome sequencing
Genomic DNA derived from the probands of the two kin-
dreds (1ug/sample) was sheared to an average fragment size 
of 300bp. DNA libraries were prepared using the KAPA DNA 
library preparation kits for Illumina sequencing platforms. 
Exons were captured using a Roche NimbleGen SeqCap 
EZ library probe and the captured libraries were sequenced 
on a HiSeq2500. Processing of image files was performed 
using standard protocol. Alignment to Hg19 reference was 
performed using Burrows–Wheeler Aligner (BWA v0.7.15). 
Picard v2.5.0 was used to mark duplicate and low‐quality 
reads. Finally, GATK (Mckenna et al., 2010) was used for 
variant calling.
2.4 | WES variant calling pipeline
Resulting variants were annotated with Annovar (Wang, 
Li, & Hakonarson, 2010) to evaluate their effect on coding 
sequences, allele frequency in the general population, and 
the predicted level of pathogenicity. Synonymous, intronic, 
intergenic, and untranslated region (UTR) variants were 
removed, along with variants with low read depth support 
(>20). Variants were intersected with a manually curated 
list of 594 lipid metabolism candidate genes including those 
in lipid metabolism pathways and genome‐wide associated 
study (GWAS) hits (Table S1). Using reported allele fre-
quencies from the GnomAD, TOPMED, and ExAC, common 
variants with a minor allele frequency >1% were discarded, 
except for two potentially damaging variants. Minor allele 
frequencies, prior evidence of disease causality, and patho-
genicity scores predicted by SIFT (Ng & Henikoff, 2003) 
and Polyphen‐2 (Adzhubei, Jordan, & Sunyaev, 2013) were 
used to prioritize variants during the curation of the filtered 
variant list. We put emphasis on variants in genes with strong 
previous clinical and biochemical evidence. We ranked the 
remaining variants based on SIFT and Polyphen‐2 algorithm 
scores. The chosen variants were then manually verified 
using Sanger sequencing.
2.5 | Final variant assessment
After the above described filtering process, we selected eight 
potentially damaging variants for each kindred to study fur-
ther. These 16 variants were examined using Sanger sequenc-
ing using DNA from the appropriate family members. Sanger 
sequencing was performed using BigDye Terminator v3.1 
and a 3730xl DNA Analyzer, Applied Biosystems on PCR 
products generated from primers designed using MacVector 
software (MacVector, Inc.).
2.6 | 10x Genomics whole 
genome sequencing
Following WES, 10xG WGS was also performed on the fa-
ther of the Caucasian proband (Figure 1; subject 2–3). This 
was because a fresh blood sample was required here and 
we wanted to avoid drawing blood again from this child. 
High molecular weight genomic DNA extraction, sam-
ple indexing, and generation of partition barcoded libraries 
were performed according to 10x Genomics (Pleasanton) 
Chromium Genome User Guide and as published previously 
(Weisenfeld, Kumar, Shah, Church, & Jaffe, 2017). Raw 
reads were processed and aligned to the reference genome 
using 10x Genomics' Long Ranger software with the “wgs” 
pipeline with default settings. Deletion coordinates generated 
by Long Ranger overlapped with the disease relevant gene 
list and the LDLR exon 1 deletion rose to the top of our vari-
ant candidate list. The LDLR deletion mutation observed here 
was confirmed by Sanger sequencing using primers spanning 
the breakpoint: forward: 5'‐agctcctagaacttgcctatcct‐3' and re-
verse 5'‐gaggctgtctctctgcaactaat‐3'.
2.7 | LDLR 3kb Exon 1 deletion 
screening assay
A PCR‐based diagnostic assay was established to detect the 
presence of the LDLR 3kb deletion which eliminates the pro-
moter region as well as exon 1. We followed the approach of 
Simard et al (Simard et al., 2004) to develop a multiplex PCR 
assay with two primers flanking the deletion breakpoints (as 
determined using 10xG WGS) and two primers within the 
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deleted region to detect the presence of a wild‐type allele. 
The first pair of primers were: 5'‐agctcctagaacttgcctatcct‐3' 
and 5'‐tcgccacagagcacagcggaa‐3', which generate a 254  bp 
product from the mutant allele. The second pair of primers 
were: 5'‐caacaaatcaagtcgcctgcc‐3' and 5'‐tgccattaccccacaa-
gtctc‐3', which yield a 481  bp product from the wild‐type 
allele. We used this assay to screen all family members in 
kindred 1, and also a cohort of patients with elevated LDL‐C. 
In this same cohort, using the previously described method 
(Simard et al., 2004) we found three patients with the French‐
Canadian LDLR exon 1 15.9 kb deletion (unpublished obser-
vations: CRP, JPK, MJM).
2.8 | Ancestry determination for the LDLR 
3kb Exon 1 deletion
To confirm that the patient was of European descent, we lev-
eraged publicly available single nucleotide polymorphism 
(SNP) genotyping data from the Human Genome Diversity 
Project (HGDP; download link: http://hagsc.org/hgdp/
data/hgdp.zip). Tri‐allelic variants, sex chromosome vari-
ants, and variants with MAF <0.05 were discarded. Filtered 
variants were merged with the proband's vcf file followed by 
LD pruning (plink v1.9 –indep‐pairwise 1,000 5 0.5) using 
r2 = 0.5 as the cutoff. Principal components analysis (PCA) 
was performed using plink and the top two PCs were used 
for plotting. Super‐population labels were assigned based on 
a previous study (Mallick et al., 2016). To ascertain the an-
cestral origin of the LDLR exon 1 deletion, we utilized the 
phased SNPs generated from 10xG Long  Ranger  pipeline. 
We modeled the expected conditional probability of observ-
ing the proband's genotype flanking the deletion events given 
population allele frequencies based on the HGDP dataset 
(Supplementary Methods).
3 |  RESULTS
3.1 | Clinical and other characteristics of 
the patients
3.1.1 | Kindred 1
The proband with a clinical diagnosis of HoFH was a 5‐year 
old Caucasian girl (Figure 1, subject 1–1) who presented 
F I G U R E  1  Pedigree of a Caucasian‐American family showing the distribution of the APOB (c.G689T: p.G230V) and LDLR (c.G1775A: 
p.G592E and exon1 3kb deletion) mutations. Lipid values are in mg/dl. Ages and body mass indexes are those at time of drawing blood
1
2
3
2 2
?
??
TC 169 TG 57
HDL 56 LDL 102
TC 273 TG 86
HDL 85 LDL 171
TC 181 TG 95
HDL 32 LDL 130
TC 790 TG 90
HDL 36 LDL 719
TC 379 TG 109
HDL 42 LDL 315
TC 297 TG 52
HDL 55 LDL 232
TC 264 TG 50
HDL 62 LDL 192
TC 358 TG 55
HDL 46 LDL 301
TC 463 TG 162
HDL 48 LDL 383
TC 300 TG 54
HDL 68 LDL 221
TC 220 TG 120
HDL 50 LDL 146
TC 496 TG 108
HDL 81 LDL 393
TC 463 TG 162
HDL 48 LDL 383
1-1 1-2 1-3 1-4 1-5 1-6
2-1 2-2 2-3 2-4 2-5
3-1 3-2 3-3 3-4 3-5
?
APOB c.G689T: p.G230V
LDLR c.G1775A: p.G592E
LDLR exon1 3kb deletion
age 43
age 75
age 9age 6 age 13
age 41
age 70
age 44
age 27age 31
age 56
age 75
3-3
age 60
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in the UCSF Pediatric Lipid Clinic with severely elevated 
LDL‐C (719 mg/dl), tuberous and tendon xanthomas. Also, 
her plasma level of HDL cholesterol (HDL‐C) was abnor-
mally low (36 mg/dl). Her father (subject 2–3) and paternal 
grandmother (subject 3–3) have elevated LDL‐C consistent 
with HeFH, and each had coronary bypass surgery at ages 
43 and 60, respectively. Her mother (subject 2–2), mater-
nal aunt (subject 2–1) and maternal grandfather (subject 
3–2) have elevated levels of LDL‐C. The proband has an 
older sister (subject 1–2) and brother (subject 1–3), both 
with HeFH.
3.1.2 | Kindred 2
In the kindred of Mexican ancestry, the proband (Figure 2, 
1–1) was born with cutaneous xanthomas. She was referred 
to the UCSF Pediatric Lipid Clinic at age 21 months where a 
clinical diagnosis of HoFH was made. She had severe hyper-
cholesterolemia with an LDL‐C of 672 mg/dl. By age 5 years 
her LDL‐C was 925 mg/dl. Her plasma level of HDL choles-
terol (HDL‐C) was low (20 mg/dl). A younger sister (subject 
1–3) was subsequently seen at the clinic with the same pheno-
type and more extensive cutaneous xanthomas at birth. At age 
7 months her LDL‐C was 791 mg/dl, and HDL‐C was 25 mg/
dl. Another sister (subject 1–2) and the parents (subjects 2–1 
and 2–2) all presented with a phenotype of HeFH. Two of the 
proband's grandparents are first cousins (the paternal grand-
mother is a first cousin of the maternal grandmother).
3.2 | Whole exome sequencing and whole 
genome sequencing: kindred 1
Eight potentially deleterious mutations (Table 1), revealed 
by WES of DNA from the proband of kindred 1 (subject 
1–1; Figure 1), were verified and assessed further by Sanger 
sequencing using all the available DNA samples from the 
rest of this family. However, the pattern of inheritance of 
these eight heterozygous variants did not fully cosegregate 
with the elevated levels of LDL‐C in this family (Table 
2). Notably, subject 1–3, despite his high level of LDL‐C 
(232 mg/dl), did not carry either of the potentially deleterious 
LDLR (p.G592E) or APOB (p.G230V) variants. To compre-
hensively and robustly evaluate the genome in an unbiased 
manner, we utilized Linked‐Reads WGS (10x Genomics, 
Inc.) in an attempt to identify potential disease‐causing 
structural variants that might have gone undetected by WES. 
10xG WGS was chosen because it has been reported that 
the use of virtual long‐reads allows for a much higher SV 
detection sensitivity (Wong, Levy‐Sakin, & Kwok, 2018). 
This revealed a heterozygous 2,977 bp deletion that included 
all of exon 1 (Figure 3). This mutation was confirmed using 
Sanger sequencing (Figure 4) of a PCR product using prim-
ers spanning the indicated breakpoint. This sequencing re-
vealed an additional four bases (TTCG) between the deletion 
junction (Figure 4). To the best of our knowledge, this de-
letion has not been reported previously. Using the genomic 
information, we validated that this proband of kindred 1 was 
of European descent (Figure 5). Furthermore, we analyzed 
the phased SNPs flanking the LDLR exon 1 deletion and pre-
dicted that this deletion allele was most likely to be origi-
nally derived from a Russian ancestor (Figure 6), which is 
consistent with the patient's self‐reported family migration 
history.
To detect this 3kb deletion in other family members, and 
in a population of patients with elevated levels of LDL‐C, we 
established a multiplex PCR assay similar in design to that 
described by Simard et al., (2004). Figure 7 (an agarose gel) 
shows the pattern of inheritance in kindred 1 with five family 
members carrying this mutation, including the proband (sub-
ject 1–1) and, notably, her brother (subject 1–3). The 481 bp 
fragment (Figure 7) is located within the deleted region and is 
a control for the presence of the wild‐type allele, whereas the 
254 bp band is a breakpoint‐spanning fragment indicating the 
presence of the 3kb deletion allele. We subsequently screened 
641 unrelated patients who were recruited into the UCSF 
Genomic Resource in Arteriosclerosis (GRA) (Pullinger et 
al., 2008; Shiffman et al., 2005), with age and sex‐adjusted 
levels of LDL‐C above the 95th percentile, but did not detect 
any additional patients with this exon 1 3kb deletion.
The pattern of inheritance of the two LDLR mutations, 
in addition to the potentially damaging novel APOB variant 
(c.G689T: p.G230V) in kindred 1 is shown in Figure 1 and 
Table 2. The two LDLR mutations now account for the pat-
tern of LDL‐C levels. The degree to which the APOB variant 
contributes an additional adverse effect is not clear, especially 
as no one in the kindred carries that variant in the absence of 
a deleterious LDLR mutation.
F I G U R E  2  Pedigree of a Mexican‐American family showing the 
distribution of the LDLR frameshift mutation (c.337dupG p.E113fs). 
Lipid values are in mg/dl. Ages and body mass indexes are those at 
time of drawing blood
1
2
TC 714 TG 120
HDL 20 LDL  672
age <2
TC 257 TG 165
HDL 23 LDL 205
age 3
TC 868 TG 110
HDL 25 LDL 791
age 2
TC 326 TG 59
HDL 56 LDL 266
age 26
TC 298 TG 143
HDL 30 LDL 243
age 32
1-1 1-2 1-3
2-1 2-2
BMI 21.3 BMI 28.3
BMI 18.5 BMI 18.2BMI 17.5
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The proband, in addition to her high level of LDL‐C, 
has a greatly decreased level of HDL‐C (36  mg/dl); less 
than the 5th percentile for her age (Lipid Research Clinics 
Program, 1980). No other member of the kindred has a 
level of HDL‐C that low. Two of the potentially damaging 
variants listed in Table 1 are in genes that have been di-
rectly associated with low levels of HDL‐C (Lange, Willer, 
& Rich, 2015). These are ABCA1 (ATP binding cassette 
subfamily A member 1) p.K776N and LCAT (lecithin‐cho-
lesterol acyltransferase) p.S232T. The first of these sub-
stitutions, which occurs in the 5th transmembrane helix 
of the ABCA1 protein, is a more likely cause of the low 
HDL‐C based on several damaging predictions (Table 1), 
and because the residue is conserved. However, two other 
carriers (subjects 2–3 and 3–3) do not have notably low 
HDL‐C. Among the other potentially damaging variants, 
MYL5 (myosin light chain 5) p.F88S, is in a gene that is 
one of 10 shown to be regulated by the master trans regula-
tor KLF14 (Consortium et al., 2011), itself associated with 
levels of HDL‐C (Lange et al., 2015) and type 2 diabetes. 
An additional carrier (subject 2–3), however, has a normal 
level of HDL‐C.
3.3 | Exome and other sequencing: 
kindred 2
Eight potentially deleterious variants detected using exome 
sequencing of DNA from the proband in kindred 2 (Table 
3) were verified, and the rest of the family was screened for 
them using Sanger sequencing. Table 4 and Figure 2 show 
the distribution of these variants within the family. LDLR 
mutation (p.E113fs) is the only mutation that is present in 
the homozygous state (subjects 1–1 and 1–3). None of the 
other seven seem to contribute to the pattern of elevated 
LDL‐C.
The pattern of inheritance of seven of the variants does 
not match the low levels of HDL‐C seen in four of the five 
family members. Only one does, that of the LPIN1 (lipin 
1) p.T249K mutant. This mutation (rs141555457) is ex-
tremely rare, and is predicted to be probably pathogenic, 
but there is no record in ClinVar. The gene codes for an 
intracellular phosphatidic acid phosphohydrolase that 
is an important regulator of lipid metabolism, especially 
hepatic VLDL‐triglyceride secretion (Chen et al., 2008). 
Deleterious mutations in Lpin1 can cause fatty liver dystro-
phy and various dyslipidemias in mice (Chen et al., 2008). 
In humans non‐alcoholic fatty liver disease (NAFLD) is 
often accompanied by low levels of HDL‐C. A heterozy-
gous carrier of a predicted pathogenic mutation in LPIN1 
was responsible for statin‐induced myopathy (Zeharia et 
al., 2008). It is not clear whether a heterozygous functional 
variant in LPIN1 could be the cause of the low levels of 
HDL‐C seen here.TA
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4 |  DISCUSSION
Here we report three patients with HoFH from two kindreds. 
The Caucasian kindred had one homozygous and seven hete-
rozygous individuals caused by two separate deleterious LDLR 
variants (exon 1 3kb deletion and p.G592E), with the possibil-
ity that a putatively deleterious novel APOB variant (p.G230V) 
contributes to the severity of FH in this family. The novel 3kb 
deletion originates from the proband's paternal family and was 
found among five individuals, while the p.G592E mutation is 
of maternal origin with four carriers. The LDLR exon 1 3kb 
deletion removing all of exon 1 and the proximal promotor is a 
null mutation, a priori. The p.G592E mutation occurs in exon 
12 in a spacer domain within the 400‐amino acid region that 
contains three cysteine‐rich repeats, each having homology to 
epidermal growth factor (EGF). This spacer region between 
EGF repeats 2 and 3 constitutes a six‐bladed beta‐propeller 
structure with six “YWTD” repeats (Jeon et al., 2001). The 
p.G592E mutation occurs within the 5th of these repeats at a 
highly conserved glycine residue (Jeon et al., 2001). This vari-
ant has been reported a number of times among Italian, Polish, 
German and Spanish patients (Bochmann et al., 2001; Górski, 
Kubalska, Naruszewicz, & Lubiński, 1998; Hobbs, Brown, & 
Goldstein, 1992; Mozas et al., 2004). With this variant, a class 
5 mutation, the receptor has some residual activity (Romano 
et al., 2010) with the protein product binding and internaliz-
ing but failing to release LDL and not recycling to the plasma 
membrane. The affected residue is highly conserved.
Additionally, in kindred 1 there were three other potentially 
deleterious variants that might affect levels of LDL‐C. One 
F I G U R E  3  Phased 10x sequencing results from subject 2–3 in kindred 1 showing the breakpoints of the 3kb LDLR exon 1 deletion 
(GRCh38/hg38 coordinates)
exon 15’ breakpoint 3’ breakpoint
F I G U R E  4  Sanger chromatogram that confirms the breakpoints from 10x sequencing. The 4bp insertion lies between the breakpoints in 
chromosome 19 at nucleotides 11,198,406 (GRCh37/hg19) and 11,201,384
C902BBCE-B02__2018-06-12_B02 Fragment base #346. Base 212 of 603
A G G C A C C C G C C A C T T C G C C C T C C T G G C G A A
Sanger sequencing showing LDLR  gene
3 kb deletion breakpoint with 4 bp insert
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was the novel p.G333V variant in MSR1 (macrophage scav-
enger receptor 1). It encodes for three types of class A macro-
phage scavenger receptors via alternate splicing. These bind, 
among numerous other ligands, modified LDL particles. The 
second variant, p.C63Y, was in PCTP (phosphatidylcholine 
transfer protein). Genetic studies indicate that the PCTP pro-
tein plays a role in HDL and VLDL metabolism and can af-
fect LDL particle size (Dolley et al., 2007). The pattern of 
inheritance of these two variants seems to suggest that they 
cannot account significantly for the elevated level of LDL‐C. 
SPT2D1 (SPT2 chromatin protein domain containing 1) has 
been widely reported to be associated with plasma levels of 
total cholesterol (Asselbergs et al., 2012; Lange et al., 2015; 
Teslovich et al., 2010). The p.K107del, in this gene seems un-
likely to be causative here because one carrier (subject 3–1) 
has a level of LDL‐C in the normal range.
The proband in kindred 1 had a significantly decreased 
level of HDL‐C. She is a carrier of the ABCA1 p.K776N 
variant, which at first sight appears as a possible cause here. 
However, a previous study showed that female carriers did 
not have lower levels of HDL‐C compared to noncarriers 
(Frikke‐Schmidt, Nordestgaard, Schnohr, Steffensen, & 
Tybjaerg‐Hansen, 2005). Another report claimed that it did 
not demonstrate an “unequivocal segregation” in a family 
study (Alrasadi, Ruel, Marcil, & Genest, 2006). ClinVar re-
ports it to be “likely benign”. Also in kindred 1 there are two 
other carriers of this p.K776N variant, and neither has a no-
tably low level of HDL‐C.
LCAT (lecithin‐cholesterol acyltransferase) is another 
candidate gene associated with levels of HDL (Lange et al., 
2015). The LCAT p.S232T variant has a MAF of 0.0176, 
making  it not so uncommon  in the human population. In a 
study of those with either high (>95th percentile) or low 
HDL‐C (<5th percentile), the p.S232T variant was found 
only among those with high HDL‐C (Naseri, Hedayati, 
Daneshpour, Bandarian, & Azizi, 2014). In kindred 1 it does 
not show segregation with levels of HDL‐C. Likewise, an-
other potential cause of low HDL‐C, p.F88S variant in MYL5 
(regulated by KLF14), can probably be ruled out because the 
father has a normal level of HDL‐C and carries this variant as 
well. Unless there are other undetected damaging mutations, 
it is likely that the low HDL‐C observed in the proband is a 
consequence of the extremely high level of LDL‐C. FH het-
erozygotes and homozygotes tend to have low levels of HDL 
F I G U R E  5  PCA plot illustrating the first two principal 
components. HGDP samples are used as the reference dataset and the 
patient from our study is highlighted in black
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with homozygotes having the lowest levels, although reason 
for this is unknown (Goldstein et al., 2007).
In the second kindred, the single LDLR frameshift mutant 
(p.E113fs) is sufficient to explain the strikingly elevated levels 
of LDL‐C. This extremely rare, a priori, damaging variant has 
a pathogenic ClinVar entry. It has been previously reported 
among Mexican FH heterozygotes (Robles‐Osorio et al., 
2006). To our knowledge, the two homozygous cases that we 
report here are the first such cases to be described. Unlike the 
first kindred, the presence of low HDL‐C in the proband of 
kindred 2 does not seem to be explained simply as a result of 
the high levels of LDL‐C. The OSBPL1A (oxysterol‐binding 
protein‐like protein 1a) variant, p.C39fs (rs766116535) has 
previously been reported to be associated with decreased lev-
els of HDL‐C (Motazacker et al., 2013, 2016). This gene en-
codes intracellular oxysterol‐binding proteins that act as lipid 
(sterols and anionic phospholipids) receptors involved in lipid 
transfer and signaling. Table 4 clearly shows that the OSBPL1A 
p.C39fs does not explain the very low levels of HDL‐C seen in 
four members of this family, with the second carrier (subject 
2–1) of this variant having a normal level (56 mg/dl).
Without some other cause for the extremely low levels of 
HDL‐C, we believe that the LPIN1 variant (p.T249K) is the 
most likely suspect.
It is important to underline that the clinical management 
of HoFH patient is challenging, and knowing the underlying 
genetic defects has significant prognostic and therapeutic im-
plications. Although the application of next‐generation sequenc-
ing in clinical settings is becoming more accessible, the number 
of negative diagnostic results remains high. Here, we were able 
to pinpoint a clinically relevant structural variant using Linked‐
Reads in kindred 1. While analyzing SVs in the clinical context 
is still in its nascent state, the availability of sequencing tech-
nology using long‐reads or virtual long‐reads allows for much 
better detection sensitivity for SVs, thus expanding the search 
space for disease‐causing variants that have been previously in-
visible to geneticists. Subject to consideration of benefit versus 
cost, the broad implementation of more advanced WGS technol-
ogy may improve diagnoses for patients with HoFH.
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